ACR 2018: Video 1 met dr. Sander Tas, Amsterdam UMC, Locatie AMC
October 2018
ACR
tofacitinib
lange termijn effect
Open-Label
Long-Term Extension Studies up to 9.5 Years
Tas
RA
1519: Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
Dr. Sander Tas, Amsterdam UMC, Locatie AMC, licht zijn selectie toe:
Wilt u meer lezen? Log dan in.
Gerelateerde items
